Biogen's Alzheimer's Drug Sharply Slows Cognitive Decline

An experimental drug for Alzheimer's disease sharply slowed the decline in mental function in a small clinical trial, researchers reported Friday, reviving hopes for an approach to therapy that until now has experienced repeated failures.

An experimental drug for Alzheimer’s disease sharply slowed the decline in mental function in a small clinical trial, researchers reported Friday, reviving hopes for an approach to therapy that until now has experienced repeated failures.

The drug, being developed by Biogen Idec, could achieve sales of billions of dollars a year if the results from the small trial are replicated in larger trials that Biogen said it hoped to begin this year. Experts say that there are no really good drugs now to treat Alzheimer’s.

Biogen’s stock has risen about 50% since early December, when the company first announced that the drug had slowed cognitive decline in the trial, without saying by how much.

Read more at The New York Times: http://nyti.ms/19GGOkq